High circulating vascular endothelial growth factor (VEGF) is related to a better systolic function in diabetic
Gianluca Iacobellis1, Rosalba Cipriani, Annarita Gabriele
1Endocrinology, Department of Clinical Sciences, La Sapienza University, Rome, Italy. gianluca.iaco@tin.it
Insights
High vascular endothelial growth factor (VEGF) levels correlate with better heart function in diabetic hypertensive patients. VEGF may improve cardiac performance in diabetes, despite cardiac remodeling.
Area of Science:
- Cardiovascular Medicine
- Endocrinology
- Neovascularization Biology
Background:
- Vascular Endothelial Growth Factor (VEGF) is implicated in cardiac microcirculation.
- Limited data exist on VEGF's impact on cardiac function and morphology in diabetic patients.
- This study investigates VEGF's influence on cardiac performance in type 2 diabetic hypertensive individuals.
Purpose of the Study:
- To test the hypothesis that circulating VEGF levels affect cardiac performance in patients with type 2 diabetes and hypertension.
- To explore the relationship between VEGF levels and cardiac structure and function in this population.
Main Methods:
- Study included 30 patients with type 2 diabetes and hypertension, and 10 hypertensive non-diabetic controls.
- Exclusion criteria: severe cardiac, retinal, renal, or peripheral vascular damage.
- VEGF plasma levels were measured using ELISA, and echocardiographic parameters were assessed.
Main Results:
- Diabetic patients exhibited significantly higher VEGF plasma levels compared to controls (median 82 vs. 50.5 pg/mL, p=0.05).
- VEGF levels correlated with relative wall thickness (RWT) and systolic parameters in diabetic patients.
- RWT and ejection fraction (EF) were identified as independent correlates of VEGF (r²=0.274, p=0.03 and p=0.05, respectively).
Conclusions:
- Elevated VEGF plasma levels are associated with improved systolic function in diabetic hypertensive patients with cardiac remodeling.
- VEGF may play a beneficial role in enhancing cardiac performance in the context of diabetes.
Background:
VEGF seems to have a protective role on cardiac microcirculation, but no data are available on its action on cardiac function and morphology in diabetic patients. We sought to test the hypothesis that circulating VEGF levels could influence the cardiac performance in type 2 diabetic hypertensive patients.
Methods:
We studied 30 patients with type 2 diabetes and hypertension, without severe cardiac, retinal, renal and peripheral vascular damage. Ten non-diabetic hypertensive patients represented the control group. VEGF plasma levels (ELISA) and echocardiographic parameters were evaluated.
Results:
Diabetic patients had VEGF plasma levels higher than hypertensive non-diabetic subjects [median 82 (IQR 12-190) vs 50.5 (IQR 28-77) pg/mL, p=0.05]. Simple linear regression analysis showed that VEGF levels are related to relative wall thickness (RWT) and both endocardial and midwall systolic parameters in the diabetic patients. Multiple linear regression analysis showed that RWT and ejection fraction (EF) were the only independent correlates of VEGF (r2=0.274, p=0.03, p=0.05; respectively).
Conclusions:
Our data showed that high VEGF plasma levels are associated to a better systolic function in diabetic hypertensive patients with cardiac remodeling. VEGF may play a role in the improvement of cardiac performance in diabetes.
Related Concept Videos
Regulation of Angiogenesis and Blood Supply
Heart Failure II: Pathophysiology
Diabetic Retinopathy
Diabetic Nephropathy
